Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

BMS-986094

Generic Name: BMS-986094

Drug Type: Small Molecule

Chemical Formula: C_₃₀H_₃₉N_₆O_₉P

CAS Number: 1234490-83-5

Unique Ingredient Identifier: 62F4AD749Y

Overview

INX-08189 has been used in trials studying the treatment of Hepatitis C, HCV (Genotype 1), and Hepatitis C Virus.

Background

INX-08189 has been used in trials studying the treatment of Hepatitis C, HCV (Genotype 1), and Hepatitis C Virus.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

Phase 2

Withdrawn

Posted: 2012/06/28

Sponsor:Bristol-Myers Squibb

ID:NCT01629732

Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

Phase 2

Terminated

Posted: 2011/08/30

Sponsor:Bristol-Myers Squibb

ID:NCT01425970

Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects

Phase 1

Completed

Posted: 2010/11/30

Sponsor:Bristol-Myers Squibb

ID:NCT01250366

A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189 in Healthy Subjects

Phase 1

Completed

Posted: 2010/07/09

Sponsor:Bristol-Myers Squibb

ID:NCT01159808

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy